- $257.51m
- $151.24m
- $53.74m
Brief: Q32 Bio Inc Restructuring Plan Includes Reduction In Force, Which Co Expects To Substantially Complete By End Of Q2 Of 2025
Brief: Q32 Bio Inc To Discontinue Renal Basket Trial For Adx-097 To Conserve Resources
Guggenheim downgrades Q32 Bio to 'neutral' as dermatitis drug fails in part of study
U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM
U.S. STOCKS ON THE MOVE-Candel Therapeutics, Broadcom, Reddit
U.S. STOCKS ON THE MOVE-Exxon Mobil, Mondelez International, Macy's
Q32 Bio tumbles after mid-stage trial setback for dermatitis drug
U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen
Brief: Q32 Bio Provides Bempikibart Program Update, Including Next Steps For Advancing Alopecia Areata Development Program
Q32 Bio plummets as dermatitis drug fails in part of a study
Q32 Bio Inc expected to post a loss of $1.25 a share - Earnings Preview
Q32 Bio Inc reports results for the quarter ended in June - Earnings Summary
Q32 Bio Inc expected to post a loss of $1.18 a share - Earnings Preview
Brief: Q32 Bio Announces Completion Of Enrollment In SIGNAL-AD Phase 2 Trial Of Bempikibart For Atopic Dermatitis
Brief: Q32 Bio Files Prospectus Relates To Proposed Offer, Resale Or Other Disposition From Time To Time By Selling Stockholders Of Up To 1.7 Million Shares
Brief: Q32 Bio Appoints Lee Kalowski As President & CFO
Brief: Orbimed Advisors Llc Reports 18.9% Stake In Q32 Bio Inc As Of March 26 - SEC Filing
Brief: Homology Medicines Board Of Directors Approved A Reverse Stock Split Ratio Of 1-For-18
Brief: Homology Medicines Inc says On February 22, A Purported Homology Stockholder Filed A Complaint In Court Against Co And Members Of Its Board